SOLTI-1303 PATRICIA 2 randomized phase II trial of palbociclib plus trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype

Ciruelos, E. M.Garcia, A. A.Cortes, J.Pernas Simon, S.Garate, E.Mele, M.Montano, A.Martinez-Janez, N.Oliveira, M.de la Haba-Rodriguez, J.Vega, E.Perello Martorell, A.Bermejo De Las Heras, B.Cantos Sanchez De Ibarguen, B.Martinez, E.Vila Navarro, E.Pascual, T.Gonzalez-Farre, X.Villagrasa, P.Prat, A.2025-01-072025-01-072021-05-080923-7534https://hdl.handle.net/10668/25898enSOLTI-1303 PATRICIA 2 randomized phase II trial of palbociclib plus trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtypeconference outputopen access10.1016/j.annonc.2021.03.1441569-8041http://www.annalsofoncology.org/article/S092375342101022X/pdf648924400134